TY - JOUR
T1 - Behavioral Counseling and Varenicline Treatment for Smoking Cessation
AU - Swan, Gary E.
AU - McClure, Jennifer B.
AU - Jack, Lisa M.
AU - Zbikowski, Susan M.
AU - Javitz, Harold S.
AU - Catz, Sheryl L
AU - Deprey, Mona
AU - Richards, Julie
AU - McAfee, Timothy A.
PY - 2010/5
Y1 - 2010/5
N2 - Background: Smoking remains the primary preventable cause of death and illness in the U.S. Effective, convenient treatment programs are needed to reduce smoking prevalence. Purpose: This study compared the effectiveness of three modalities of a behavioral smoking-cessation program in smokers using varenicline. Methods: Current treatment-seeking smokers (n=1202) were recruited from a large healthcare organization between October 2006 and October 2007. Eligible participants were randomized to one of three smoking-cessation interventions: web-based counseling (n=401); proactive telephone-based counseling (PTC; n=402); or combined PTC and web counseling (n=399). All participants received a standard 12-week FDA-approved course of varenicline. Self-report determined the primary outcomes (7-day point prevalent abstinence at 3- and 6-month follow-ups); the number of days varenicline was taken; and treatment-related symptoms. Behavioral measures determined utilization of both the web- and Phone-based counseling. Results: Intent-to-treat analyses revealed relatively high percentages of abstinence at 3 months (38.9%, 48.5%, 43.4%) and at 6 months (30.7%, 34.3%, 33.8%) for the web, PTC, and PTC-web groups, respectively. The PTC group had a significantly higher percentage of abstinence than the web group at 3 months (OR=1.48, 95% CI=1.12, 1.96), but no between-group differences in abstinence outcomes were seen at 6 months. Conclusions: Phone counseling had greater treatment advantage for early cessation and appeared to increase medication adherence, but the absence of differences at 6 months suggests that any of the interventions hold promise when used in conjunction with varenicline.
AB - Background: Smoking remains the primary preventable cause of death and illness in the U.S. Effective, convenient treatment programs are needed to reduce smoking prevalence. Purpose: This study compared the effectiveness of three modalities of a behavioral smoking-cessation program in smokers using varenicline. Methods: Current treatment-seeking smokers (n=1202) were recruited from a large healthcare organization between October 2006 and October 2007. Eligible participants were randomized to one of three smoking-cessation interventions: web-based counseling (n=401); proactive telephone-based counseling (PTC; n=402); or combined PTC and web counseling (n=399). All participants received a standard 12-week FDA-approved course of varenicline. Self-report determined the primary outcomes (7-day point prevalent abstinence at 3- and 6-month follow-ups); the number of days varenicline was taken; and treatment-related symptoms. Behavioral measures determined utilization of both the web- and Phone-based counseling. Results: Intent-to-treat analyses revealed relatively high percentages of abstinence at 3 months (38.9%, 48.5%, 43.4%) and at 6 months (30.7%, 34.3%, 33.8%) for the web, PTC, and PTC-web groups, respectively. The PTC group had a significantly higher percentage of abstinence than the web group at 3 months (OR=1.48, 95% CI=1.12, 1.96), but no between-group differences in abstinence outcomes were seen at 6 months. Conclusions: Phone counseling had greater treatment advantage for early cessation and appeared to increase medication adherence, but the absence of differences at 6 months suggests that any of the interventions hold promise when used in conjunction with varenicline.
UR - http://www.scopus.com/inward/record.url?scp=77950814384&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77950814384&partnerID=8YFLogxK
U2 - 10.1016/j.amepre.2010.01.024
DO - 10.1016/j.amepre.2010.01.024
M3 - Article
C2 - 20409497
AN - SCOPUS:77950814384
VL - 38
SP - 482
EP - 490
JO - American Journal of Preventive Medicine
JF - American Journal of Preventive Medicine
SN - 0749-3797
IS - 5
ER -